Abstract: In one aspect, a network system includes a user interface which allows a user to interact with the network system. An agent server is coupled to the user interface. The agent server manages the operation of the network system. Furthermore, the agent server in conjunction with the user interface is operable to create or modify an agent in response to interaction by the user. In another aspect, a network system includes an agent server which manages the operation of the network system. An agent is operable to utilize a service within the network system. A service wrapper, associated with the service, cooperates with the agent server to mediate interaction between the service and the agent.

Abstract: Determining and simultaneously using a circuit for a mobile device couple to a base station, the circuit may comprise an identification signal detector for receiving a first identification signal corresponding to a first module and a second identification signal corresponding to a second module in the mobile device. The circuit may comprise a receiver for receiving a plurality of signals from the base station; said plurality of signals is configured to set up communication between the mobile device and the base station. The circuit may comprise a calculator for calculating a plurality of parameters in response to the first identification signal, second identification signal and said plurality of signals received from said base station.

Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.

Abstract: A method and system is disclosed for detecting indicators using a multi-stage and multi-threshold detection mechanism so that a mobile terminal can be removed from an idle mode appropriately.

Abstract: A wireless access terminal is configured to enter into a freeze state where the wireless access terminal temporarily stops decoding and receiving data for a first access network, when the wireless access terminal's modem tunes away from the first access network to monitor signals from a second access network. When the modem tunes back, the wireless access terminal continues processing signals from the first access network without re-initializing with the first access network. When the terminal enters the freeze state, state variables for the terminal's various protocols, including layer 1, layer 2, and modem controller protocols can be stored so that the protocols can continue processing when the modem tunes back, without the need to reinitialize.

Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

Abstract: A method and system is disclosed for detecting paging indicators using a multi-stage and multi-threshold detection mechanism so that a mobile terminal can be removed from an idle mode appropriately. After receiving a first paging indicator, it is determined whether a first indicator measurement corresponding to the first paging indicator is between a first and a second predetermined thresholds. After receiving a second paging indicator which may be a temporal diversity counterpart of the first paging indicator, a second indicator measurement derived based on both the first and second paging indicators is compared against a third predetermined threshold, wherein the mobile terminal is removed from the idle mode when both comparisons are appropriately conducted.

Abstract: The present invention relates to arene connected polyamine macrocyclic derivatives represented by general formula I, pharmaceutically acceptable salts or hydrates thereof which have anti-HIV activities, in which the definitions of substituents are as defined in the description; to preparation methods of the compounds of formula I; to pharmaceutical compositions containing the compounds of formula I or their pharmaceutically acceptable salts or hydrates; to the use of the compounds of formula I or their pharmaceutically acceptable salts or hydrates for the preparation of a medicament for the treatment and prevention of HIV-associated diseases.

Abstract: Determining and simultaneously using a base station coupled to a mobile device, the base station comprising a detector for receiving a first identification signal corresponding to a first module and a second identification signal corresponding to a second module from the mobile device. A transmitter for sending a plurality of signals to the mobile device, said plurality of signals is configured to set up communication between the mobile device and the base station. A receiver for receiving a plurality of parameters for determining whether the second module is able to attach to the base station; and a processor for connecting the first and second module in the mobile device to the base station simultaneously in response to a plurality of slots by time multiplexing and the plurality of parameters when the second module is acceptable by the base station, wherein said plurality of slots are determined by the base station.

Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

Abstract: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.

Abstract: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.

Abstract: The present invention relates to a method of characterizing biochips with matrix-assisted laser desorption/ionization and time of flight mass spectrometry (MALDI-TOF MS).

Abstract: The invention is related to a method for purification of recombinant proteins using highly basic proteins from thermophilic bacteria as purification tags for use in a cation-exchange chromatography purification step. The basic proteins may be ribosomal proteins. The recombinant proteins are expressed in eukaryotic or prokaryotic host cells. The purification tag will typically have a pl above about 9 and comprise from about 15 to about 250 amino acid residues.

Abstract: Fusion proteins comprising a first protein fused to hemopexin are provided, said fusion proteins exhibit an increased circulation time.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1: wherein Z?, L?, M?, R1, X and D are defined herein.

Abstract: The present invention provides compounds, which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1/D5 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Abstract: The present invention relates to a striping apparatus and a striping method. The apparatus for stripping a film from a product comprising a transfer device for transferring the product; a film stripping device disposed above a stripping operation area of the transfer device for stripping the film from the product; and a plurality of guiding devices disposed on both sides of the transfer device in the stripping operation area for guiding the transfer direction of the product.

Abstract: The present invention provides novel biocompatible macromonomers, hydrogels, methods of synthesis and methods of use thereof. The biocompatible hydrogels of the present invention are prepared using native chemical ligation (NCL), in which a thioester readily reacts with a N-terminal thiol (cysteine) through transesterification and rearrangement to form an amide bond through a five-member ring intermediate.

Abstract: The present invention discloses a process for refining Ganoderma spore polysacchoride. The process comprise the step of: Remove the impurity in the Ganoderma spores, warm water extraction, alcohol precipitation, separate precipitate, obtain the impure polysacchoride, adjust pH to 7.5-8.5, centrifuge to removal deposit, take out supernatent, add H2O2 to decolor, deproteined by sevag method, dialyses, alcohol precipitation, wash the precipitate, dry in the vacuum to get the pure Ganoderma spore polysacchoride.